According to a recent LinkedIn post from DeepScribe, the company is spotlighting a new episode of its “Beyond the Chart” oncology podcast featuring Alicia Zhou, PhD, now CEO of the Cancer Research Institute. The discussion reportedly explores upcoming research advances in oncology and the role artificial intelligence could play in building future foundations for cancer research.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that Zhou compares her leadership approach at CRI to startup-style operations that blend scientists and technologists toward mission-driven goals. For investors, the focus on AI in oncology and engagement with a prominent research leader may signal DeepScribe’s intent to position itself more deeply within the healthcare AI and cancer research ecosystem, potentially enhancing brand visibility and strategic credibility in a competitive market.
By promoting long-form expert content and announcing that the conversation extends into a second part, the post suggests an effort to build an ongoing thought-leadership platform rather than one-off marketing. This type of engagement could help attract clinical partners, talent, and prospective customers, which over time may support pipeline development and strengthen DeepScribe’s standing in the broader healthcare technology landscape.